XML 110 R97.htm IDEA: XBRL DOCUMENT
v3.24.0.1

COMMITMENTS AND CONTINGENCIES (Details) $ in Millions | 12 Months Ended |  |
--- | --- | --- | ---
Dec. 31, 2023 USD ($) third_party | Sep. 30, 2023 USD ($) | Dec. 31, 2022 USD ($)
Commitments and Contingencies [Line Items] |  |  |
Contingent payments upon achievement of certain development and regulatory activities and commercial sales and licensing milestones | $ 763.3 |  |
Amount due in 2024 | 30.1 |  |
Purchase commitment | 354.1 |  |
Purchase commitment expected to be paid in 2024 | 325.9 |  |
Shareholder vs BioMarin Pharmaceutical Inc |  |  |
Commitments and Contingencies [Line Items] |  |  |
Estimated long-term loss contingency |  | $ 39.0 | $ 13.0
Amount awarded to other party released | 39.0 |  |
Early Stage Development Program | Third Party |  |  |
Commitments and Contingencies [Line Items] |  |  |
Contingent payments upon achievement of certain development and regulatory activities and commercial sales and licensing milestones | $ 591.5 |  |
Number of third parties | third_party | 2 |  |

X
- Definition Commitments and contingencies. + References No definition available. + Details
Name: | bmrn_CommitmentsAndContingenciesLineItems
Namespace Prefix: | bmrn_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Contingent payments upon achievement of certain development and regulatory activities and commercial sales and licensing milestones. + References No definition available. + Details
Name: | bmrn_ContingentPaymentsReasonablyPossibleUponAchievementOfCertainDevelopmentAndRegulatoryActivitiesCommercialSalesAndLicensingMilestones
Namespace Prefix: | bmrn_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Contingent Payments Reasonably Possible Upon Achievement Of Certain Development And Regulatory Activities Commercial Sales And Licensing Milestones, To Be Paid, Year One + References No definition available. + Details
Name: | bmrn_ContingentPaymentsReasonablyPossibleUponAchievementOfCertainDevelopmentAndRegulatoryActivitiesCommercialSalesAndLicensingMilestonesToBePaidYearOne
Namespace Prefix: | bmrn_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Number Of Third Parties + References No definition available. + Details
Name: | bmrn_NumberOfThirdParties
Namespace Prefix: | bmrn_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount awarded to other party in judgment or settlement of litigation. + References No definition available. + Details
Name: | us-gaap_LitigationSettlementAmountAwardedToOtherParty
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Reflects the estimated amount of loss from the specified contingency as of the balance sheet date. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482425/460-10-50-3 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482425/460-10-50-2 + Details
Name: | us-gaap_LossContingencyEstimateOfPossibleLoss
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier. + References No definition available. + Details
Name: | us-gaap_PurchaseObligation
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of purchase arrangement to be paid in next fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + References No definition available. + Details
Name: | us-gaap_PurchaseObligationDueInNextTwelveMonths
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Details
Name: | srt_LitigationCaseAxis=bmrn_ShareholderVsBioMarinPharmaceuticalIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=bmrn_EarlyStageDevelopmentProgramMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=bmrn_ThirdPartyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |